A Single-Center, Open-Label, Phase I Study of Single-Agent GMX1777 Administered as a 24-Hour Infusion Every 3 Weeks to Patients With Refractory Solid Tumors or Lymphomas
This is a single-center, open-label, Phase I study of single-agent GMX1777 administered
every 3 weeks to patients with CLL, MM, refractory solid tumors or lymphomas. No
investigational or commercial agents or therapies other than those described may be
administered with the intent to treat the patient's malignancy.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Determine the recommended Phase II dose; Characterize the dose-limiting toxicities; Determine the pharmacokinetic parameters
Mark Berger, MD
Gemin X, Inc.
United States: Food and Drug Administration
|Georgetown University Medical Center||Washington, District of Columbia 20007|
|Maria Delioukina||Duarte, California 91010|
|University of Maryland at Baltimore||Baltimore, Maryland 21201|